Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.
about
Myeloid-derived cells are key targets of tumor immunotherapyDifferential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy.Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapyDownregulation of CD40 expression contributes to the accumulation of myeloid-derived suppressor cells in gastric tumors.Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.Multifaceted antitumor responses to activating anti-CD40 antibody therapy combined with immunomodulatory or targeted agents.IL-15 deficient tax mice reveal a role for IL-1α in tumor immunitySystemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent mannerThe split personality of NKT cells in malignancy, autoimmune and allergic disordersAdjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expressionCD40 controls CXCR5-induced recruitment of myeloid-derived suppressor cells to gastric cancerImmunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapiesInducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer.Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.Macrophages in cancer and infectious diseases: the 'good' and the 'bad'.The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.Towards curative cancer immunotherapy: overcoming posttherapy tumor escape.The use of agonistic anti-CD40 therapy in treatments for cancer.Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists.CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytesTh1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro.Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer
P2860
Q28388246-32E07BAF-8380-406B-BC95-7046C57ABB53Q33572965-2268D75E-A555-4F48-ADFD-21F8EB7B20DCQ33723734-7119FEBF-F9CA-4124-8151-36C50125DCCEQ33844271-71F32549-BDB2-4280-8AAB-FAA834060567Q33863928-DBC7E0D1-8334-4D89-84DB-A632260D44F3Q34243432-06736FD4-5818-4F1A-A29D-3A4FB3BD47F6Q34934017-72B9D734-1BEE-4EA6-B2EF-D1AEAA97D255Q35085001-84558F68-6257-4FA2-97AF-F086029511B9Q35572171-C0EB74BE-D714-4C0B-AF39-B76DCB908EF5Q35586581-E87CD2BB-08E3-4378-A86F-286F60F97D9FQ35590727-78873525-AC6A-4EE5-98BE-F0F2CAA94F01Q35886450-CF0288AD-6252-4A9D-94BF-C28031121FC8Q36322948-A34B9C4A-0EF2-4287-96B9-FBEC2CC772BCQ36629448-DB034EFD-3F85-4066-9DB5-50BE8279EF6BQ37047061-136D9271-6262-4479-A96E-947E837EC9C3Q37619697-D0E3D1D3-3D63-49D5-B2BA-08BCFA4DF909Q37706248-F2F17518-A428-4C7B-8C89-3E388C6A161CQ37829504-4C6B6203-5A0E-42AD-83CF-150C6C3CC9AAQ37945300-21284A43-038D-41A2-8C77-FA17F27ECBC1Q38021845-86E45EC4-C261-48A0-9185-451752621757Q38025094-5C43E443-FE1E-4AFC-8906-1B3B7AB066DBQ38026924-33FB9DDE-8CCC-4203-94CC-1F2A77EA1E23Q38786054-E29C6EF0-789E-49B5-A690-9570C6E700D3Q39061506-043075BA-1A62-4548-BB98-97353491CBC2Q42385826-745F08D0-1FA1-47E4-AEAE-5EEB8C5582B0Q43428464-9506FA4B-AF1F-47E7-9D71-7DE12C689754Q58750668-DED6D20D-C6A4-48E6-957B-92A9ABA669D4
P2860
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Successful immunotherapy with ...... essive tumor microenvironment.
@en
Successful immunotherapy with ...... essive tumor microenvironment.
@nl
type
label
Successful immunotherapy with ...... essive tumor microenvironment.
@en
Successful immunotherapy with ...... essive tumor microenvironment.
@nl
prefLabel
Successful immunotherapy with ...... essive tumor microenvironment.
@en
Successful immunotherapy with ...... essive tumor microenvironment.
@nl
P2093
P2860
P356
P1476
Successful immunotherapy with ...... essive tumor microenvironment.
@en
P2093
Anthony J Scarzello
Dejan Micic
Jeff J Subleski
Jimmy K Stauffer
Jonathan M Weiss
Kory Alderson
Robert H Wiltrout
Timothy C Back
Veronica L Hall
William J Murphy
P2860
P304
19455-19460
P356
10.1073/PNAS.0909474106
P407
P577
2009-11-05T00:00:00Z